Trials / Completed
CompletedNCT00934375
A 28-Week Open Label Extension Study Evaluating Safety and Tolerability of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 145 (actual)
- Sponsor
- Eisai Inc. · Industry
- Sex
- All
- Age
- 45 Years – 90 Years
- Healthy volunteers
- —
Summary
This is a multi-center, open-label study of 28 weeks duration in subjects with Mild Cognitive Impairment who have completed the double-blind study (E2020-A001-412).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aricept (donepezil hydrochloride) | 5 mg or 10 mg of donepezil hydrochloride (Aricept) taken orally once a day. |
| DRUG | placebo |
Timeline
- Start date
- 2006-02-01
- Primary completion
- 2007-09-01
- Completion
- 2007-09-01
- First posted
- 2009-07-08
- Last updated
- 2014-01-14
- Results posted
- 2009-07-08
Locations
49 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00934375. Inclusion in this directory is not an endorsement.